Vinorelbine (Navelbine Oral®)

All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000453
Authors' recommendations: Oral vinorelbine (Navelbine Oral®) is recommended for use within NHS Wales as a single agent (in line with current NICE recommendations for IV vinorelbine), for the treatment of advanced breast cancer stage III and IV relapsing after or refractory to an anthracycline-containing regimen. Oral vinorelbine (Navelbine Oral®) should only be initiated by specialists experienced in the treatment of breast cancer. Oral vinorelbine (Navelbine Oral®) should not presently be recommended for shared care.
Project Status: Completed
Year Published: 2007
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Humans
  • Vinblastine
  • Antineoplastic Agents, Phytogenic
  • Breast Neoplasms
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
Contact Email:
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.